Safety
Itacitinib 300 mg once daily was selected as the MTD in dose-escalation Part 1a/Group A and used in safety-expansion Part 1b/Group A-1 [PD-(L)1 treatment-experienced] and A-2 [PD-(L)1 treatment-naïve]. Parsaclisib 30 mg once daily was selected as the MTD/PAD in dose-escalation Part 1a/Group B, and parsaclisib 20 mg once daily and 30 mg once daily were selected for safety-expansion Part 1b/Group B-1 [PD-(L)1 treatment-experienced] and B-2 [PD-(L)1 treatment-naïve]. Taking into consideration that higher doses of parsaclisib (20 or 30 mg once daily) required prophylaxis for 